An open-label study of extended-release sodium oxybate in spasmodic dysphonia

Not Yet Recruiting Phase 1 NCT07041203

Study Description

Investigating the effects of an extended-release medication on voice symptoms in people with spasmodic dysphonia

Study Details

Registry ID:
NCT07041203
Conditions:
Spasmodic Dysphonia, Laryngeal Dystonia, Voice Tremor
Phase:
Phase 1
Target Enrollment:
8 participants
Start Date:
Age Range:
21–80 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →